Suleiman Massarweh

Stanford Medicine — United States

Biochemistry, Genetics and Molecular Biology · Life Sciences

24h-index4.5kcitations92works0.52yr avg
OpenAlex↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Estrogen and related hormone effects(40), HER2/EGFR in Cancer Research(30), Advanced Breast Cancer Therapies(26), Breast Cancer Treatment Studies(22), Cancer Treatment and Pharmacology(14)

Publications92 total

Etirinotecan Pegol (<scp>NKTR</scp>‐102) in Patients With Active Brain Metastases From Lung or Breast Cancer
Cancer Reports·2025· 1 citedOpen Access
Etirinotecan Pegol (NKTR-102) in Patients with Active Brain Metastases from Lung or Breast Cancer
2025Open Access
Supplementary Figure 2 from Blockade of AP-1 Potentiates Endocrine Therapy and Overcomes Resistance
2023Open Access
Supplementary table 2 from Blockade of AP-1 Potentiates Endocrine Therapy and Overcomes Resistance
2023Open Access
Data from Blockade of AP-1 Potentiates Endocrine Therapy and Overcomes Resistance
2023Open Access
Data from Blockade of AP-1 Potentiates Endocrine Therapy and Overcomes Resistance
2023Open Access
Supplementary Figure 1 from Blockade of AP-1 Potentiates Endocrine Therapy and Overcomes Resistance
2023Open Access
Supplementary table 3 from Blockade of AP-1 Potentiates Endocrine Therapy and Overcomes Resistance
2023Open Access
Supplementary table 4 from Blockade of AP-1 Potentiates Endocrine Therapy and Overcomes Resistance
2023Open Access
Legend for supplementay figures from Blockade of AP-1 Potentiates Endocrine Therapy and Overcomes Resistance
2023Open Access
Supplementary Figure 2 from Blockade of AP-1 Potentiates Endocrine Therapy and Overcomes Resistance
2023Open Access
Supplementary table 3 from Blockade of AP-1 Potentiates Endocrine Therapy and Overcomes Resistance
2023Open Access
Supplementary table 2 from Blockade of AP-1 Potentiates Endocrine Therapy and Overcomes Resistance
2023Open Access
Supplementary table 1 from Blockade of AP-1 Potentiates Endocrine Therapy and Overcomes Resistance
2023Open Access
Supplementary Figure 1 from Blockade of AP-1 Potentiates Endocrine Therapy and Overcomes Resistance
2023Open Access
Supplementary table 4 from Blockade of AP-1 Potentiates Endocrine Therapy and Overcomes Resistance
2023Open Access
Supplementary table 1 from Blockade of AP-1 Potentiates Endocrine Therapy and Overcomes Resistance
2023Open Access
Legend for supplementay figures from Blockade of AP-1 Potentiates Endocrine Therapy and Overcomes Resistance
2023Open Access
Supplementary Methods and Materials from Development of Resistance to Targeted Therapies Transforms the Clinically Associated Molecular Profile Subtype of Breast Tumor Xenografts
2023Open Access
Supplementary Data 1 from Development of Resistance to Targeted Therapies Transforms the Clinically Associated Molecular Profile Subtype of Breast Tumor Xenografts
2023Open Access
page 1 of 5Next →

Frequent Co-authors

Rachel Schiff(16), Edward H. Romond(13), C. Kent Osborne(10), Heidi L. Weiss(9), Mark Stevens(8), Mothaffar F. Rimawi(6), Susan G. Hilsenbeck(6), Richard Elledge(6), Chad J. Creighton(5), Jiang Shou(5), Esther P. Black(5), Brent J. Shelton(5), Carolina Gutiérrez(4), Ilenia Migliaccio(4), Mara Chambers(4), Grace Pasley(4), Jessica Moss(4), Anna Tsimelzon(3), Lavina Bharwani(3), Grazia Arpino(3)